Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26683ArticlesСтатьиUnknownRegional'naya programma lecheniya raka yaichnika IIB–IV stadiiРегиональная программа лечения рака яичника IIB–IV стадии--1509200793VOL 9, NO3 (2007)ТОМ 9, №3 (2007)394209042020Copyright ©; 2007, Consilium MedicumCopyright ©; 2007, ООО "Консилиум Медикум"2007Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26683

Обоснование расширения программы: • повышение эффективности лечения больных раком яичника (РЯ) IIB – IV стадии при прогрессировании на фоне комбинированной терапии Карбоплатин + Паклитаксел или при рецидиве заболевания в период до 6 мес (платинорезистентные больные), от 6 до 12 мес (частично платиночувствительные больные); • оценка эффективности и переносимости монотерапии Келиксом в качестве второй линии терапии больных раком яичника IIB–IV стадии; • обобщение российского опыта применения Келикса во 2-й линии терапии больных раком яичника.

Papahadjopoulous D, Allen T.N, Gabizon A., et al. Sterically Stabilized Liposomes: Improvement in Pharmacokinetics and Anti - Tumour Therapeutic Efficacy. PNAS 1991; 88:11460-64.Martin F.J, Gabizon A, Human Pharmacokinetics of Stealth_ Liposomes containing Doxorubicin, J. Cell Biochem 1992; Supplement 16E:98.North D, et al. Pharmacokinetics (PK), Tumour Localization (TL) and Safety of CAELYX (Liposomal Doxorubicin ) in AIDS Patients with Kaposi's Sarcoma (AIDS-KS). Proceedings from the American Society of Oncology, 1993; 12:51.Ozols R.B, et al. Chemotherapy for Murine Ovarian Cancer: A Rationale for IP Therapy with Adriamycin. Cancer Treat Rep., 1979; 63:269-74.Chavdury P.M, Roninson I.B. Induction of Multidrug Resistance in Human Cells by Transient Exposure to Different Chemotherapeutic Drugs. J Natl Cancer Institute, 1993; 85:632-9.Ouclard S, et al. Sensitization of Multidrug - Resistant Colon Cancer Cells to Doxorubicin Encapsulated in Liposomes. Cancer Chemother Pharmacol, 1991; 28(4):259-65.Thierry A.R, et al. Effect of Liposomes on P Glycoprotein Function in Multidrug-Resistant Cells. Biochem - Biophys Res Commun, 1992; 187:1098-105.O'Brien N. Wigler, M. Inbar et al , Reduced cardiotoxicity and comparable efficacy in phase III trial of Pegylated Liposomal Doxorubicin (Caelyx/Doxil)vs conventional doxorubicinfor first - line treatment of metaststic breast cancer Annals of Oncology, 2004, v15, p. 440-9A. N. Gordon, J.T. Fleagle, D. Guthrie, D. E. Parkin, M. E. Gore, and A. J. Lacave Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal DoxorubicinVersus Topotecan J Clin Oncol 19:3312-3322. 2001A. N. Gordon, M. Tonda, S. Sun, W. Rackoff on behalf of the Doxil Study 30-49 investigators Long - term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecologic Oncology 95 (2004) 1 -8M. Salzberg, B. Thrlimann, H. Bonnefois, D. Fink, C. Rochlitz, R. Moos, H. Senn Current Concepts of Treatment Strategies in Advanced or Recurrent Ovarian Cancer Oncology 2005;68:293-298J. Tate Thigpen, C.A. Aghajanian, D.S. Alberts, S.M. Campos, A.N. Gordon, M. Markman, D. S. McMeekin, B.J. Monk, P.G. Rose Role of pegylated liposomal doxorubicin in ovarian cancer Gynecologic Oncology 96 (2005) 10-18M. Markman, A. N. Gordon, W. P. Mc Guire, F. M. Muggia Liposomal AnthracyclineTreatment for Ovarian Cancer Semin Oncol 31(Suppl 13):91-105 , 2004NHS Review of Technology Appraisal 91. May 2005.N.Colombo, M.Gore. Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum - based chemotherapy. Crit Rev in Oncol Hematol, 2007, in pressD.Lorusso et al. Pegylated liposomal doxorubicin - related palmar - plantar erythrodysesthesia ('hand - foot' syndrome), review article, Annals Oncol, Jan 17, 2007:1-6.